Therapeutic procedure Double-Blind Method Successful Completed
Item
successful completion of 12 weeks of double-blind treatment in core protocol cval489k2302.
boolean
C0087111 (UMLS CUI [1,1])
C0013072 (UMLS CUI [1,2])
C1272703 (UMLS CUI [1,3])
C0205197 (UMLS CUI [1,4])
Study Subject Participation Status Clinical Trial Discontinued | Uncontrolled hypertension | Sitting systolic blood pressure mean | Age | Gender | Body Height
Item
patients participating in study cval489k2302 who may have discontinued prematurely due to uncontrolled hypertension defined as mssbp > 20%, but < 25% above the 95th percentile for age, gender, and height after visit 5, qualifies a patient for entry into this extension study.
boolean
C2348568 (UMLS CUI [1,1])
C0008976 (UMLS CUI [1,2])
C1444662 (UMLS CUI [1,3])
C1868885 (UMLS CUI [2])
C1319893 (UMLS CUI [3,1])
C0444504 (UMLS CUI [3,2])
C0001779 (UMLS CUI [4])
C0079399 (UMLS CUI [5])
C0005890 (UMLS CUI [6])
Renal Artery Stenosis
Item
renal artery stenosis.
boolean
C0035067 (UMLS CUI [1])
Heart failure New York Heart Association Classification
Item
current diagnosis of heart failure (nyha class ii-iv).
boolean
C0018801 (UMLS CUI [1,1])
C1275491 (UMLS CUI [1,2])
Second degree atrioventricular block | Complete atrioventricular block | Artificial cardiac pacemaker Absent
Item
second or third degree heart block without a pacemaker.
boolean
C0264906 (UMLS CUI [1])
C0151517 (UMLS CUI [2])
C0030163 (UMLS CUI [3,1])
C0332197 (UMLS CUI [3,2])
Cardiac Arrhythmia Life Threatening | ARRHYTHMIA SYMPTOMATIC
Item
concurrent potentially life threatening arrhythmia or symptomatic arrhythmia.
boolean
C0003811 (UMLS CUI [1,1])
C2826244 (UMLS CUI [1,2])
C0741212 (UMLS CUI [2])
Heart valve disease
Item
clinically significant valvular heart disease.
boolean
C0018824 (UMLS CUI [1])
ECG abnormality | Exception Left Ventricular Hypertrophy | Atrioventricular Block Controlled by Artificial cardiac pacemaker
Item
patient that demonstrates clinically significant ecg abnormalities other than those associated with left ventricular hypertrophy and av block controlled with a pacemaker.
boolean
C1832603 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0149721 (UMLS CUI [2,2])
C0004245 (UMLS CUI [3,1])
C0332298 (UMLS CUI [3,2])
C0030163 (UMLS CUI [3,3])
Solid organ transplant | Exception Kidney Transplantation | Exception Transplantation of liver | Exception Heart Transplantation | Therapeutic immunosuppression Dosage Stable | Patient Stable status
Item
previous solid organ transplantation except renal, liver or heart transplantation. renal, liver or heart transplant must have occurred at least 6 months prior to enrollment. patient must be on stable doses of immunosuppressive therapy for 3 months and deemed clinically stable by the investigator.
boolean
C0730400 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0022671 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0023911 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0018823 (UMLS CUI [4,2])
C0021079 (UMLS CUI [5,1])
C0178602 (UMLS CUI [5,2])
C0205360 (UMLS CUI [5,3])
C0030705 (UMLS CUI [6,1])
C0205360 (UMLS CUI [6,2])
Serious Adverse Event | Adverse reaction to drug
Item
patients who experienced any adverse events considered serious and drug related in protocol cval489k2302.
boolean
C1519255 (UMLS CUI [1])
C0041755 (UMLS CUI [2])
Eligibility Criteria Study Protocol
Item
other protocol-defined inclusion/exclusion criteria applied to the study.
boolean
C1516637 (UMLS CUI [1,1])
C2348563 (UMLS CUI [1,2])